To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients
Numerous immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), have been approved f...
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint...
Importance: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now s...
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune chec...
Female sex is associated with a higher risk for autoimmune diseases (ADs) and immune-related adverse...
International audienceImmune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune R...
Evidence has recently emerged on the influence of gender on the immune system. In this systematic re...
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for multiple ...
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adv...
In the past 10 years, immune checkpoint inhibitors (ICIs) have become an additional pillar of cancer...
Jennifer M Yoest Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ...
The use of immune checkpoint inhibitors (ICIs) is rapidly increasing as more combinations and clinic...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes ...
The explosion in novel cancer immunotherapies has resulted in extraordinary clinical successes in th...
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-...
Numerous immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), have been approved f...
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint...
Importance: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now s...
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune chec...
Female sex is associated with a higher risk for autoimmune diseases (ADs) and immune-related adverse...
International audienceImmune Checkpoint Inhibitors (ICI) for cancer therapy induce frequent Immune R...
Evidence has recently emerged on the influence of gender on the immune system. In this systematic re...
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for multiple ...
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adv...
In the past 10 years, immune checkpoint inhibitors (ICIs) have become an additional pillar of cancer...
Jennifer M Yoest Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ...
The use of immune checkpoint inhibitors (ICIs) is rapidly increasing as more combinations and clinic...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes ...
The explosion in novel cancer immunotherapies has resulted in extraordinary clinical successes in th...
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-...
Numerous immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), have been approved f...
Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint...
Importance: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now s...
DOI
Add to ORKG